RxDoctor Payments DataLook up a doctor →

Leonard Cohen, MD

Neurology · Aventura, FLNPI 1265427298

Payments from drug & device makers

$1,722,299in general payments, 2019–2025

Across 1,380 payments — averaging $1248.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$1.7M
  • AbbVie$42K
  • E.r. Squibb & Sons, L.L.C.$9K
  • UCB, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$868
  • plus $14K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.282$1,653,119
AbbVie(2 entities)230$42,401
E.r. Squibb & Sons, L.L.C.1$9,437
UCB, Inc.51$1,717
Teva Pharmaceuticals USA, Inc.67$1,083
Neurocrine Biosciences, Inc.66$868
Novartis51$829
EMD Serono, Inc.31$790
Pfizer44$787
Biogen36$752
AstraZeneca(2 entities)31$650
SK Life Science, Inc.25$586
Lilly USA, LLC32$562
MDD US Operations, LLC32$532
Acadia Pharmaceuticals Inc28$519
Argenx US, Inc.22$508
Adamas Pharmaceuticals, Inc.34$504
Acorda Therapeutics, Inc27$476
Lundbeck LLC21$460
Biohaven Pharmaceutical Holding Company Ltd.23$454
Amgen(2 entities)18$423
Sunovion Pharmaceuticals Inc.22$415
Tanabe Pharma America, Inc.17$405
Upsher-smith Laboratories LLC20$392
Otsuka America Pharmaceutical, Inc.14$328
Johnson & Johnson(2 entities)17$318
Biohaven Pharmaceuticals, Inc.16$305
Abbott5$304
Kyowa Kirin, Inc.14$263
Sanofi14$227
Boston Scientific4$213
Amneal Pharmaceuticals LLC9$181
Avion Pharmaceuticals9$161
Idorsia Pharmaceuticals US Inc6$139
GE HealthCare7$121
Avanir Pharmaceuticals, Inc.6$108
Greenwich Biosciences, Inc.5$101
Genentech USA, Inc.3$75
Axsome Therapeutics, Inc.3$72
Supernus Pharmaceuticals, Inc.5$71
Aquestive Therapeutics, Inc.3$71
Scilex Pharmaceuticals Inc.3$67
Neurelis, Inc.3$65
Merz Pharmaceuticals, LLC3$56
Jazz Pharmaceuticals Inc.2$54
Alnylam Pharmaceuticals Inc.2$53
Livanova USA, Inc.2$43
Currax Pharmaceuticals LLC3$40
Averitas Pharma Inc.2$40
Octapharma USA, Inc.2$38
CSL Behring1$22
GRT US Holding, Inc.1$19
Corium, LLC1$17
Almatica Pharma LLC1$16
Promius Pharma LLC1$15
Vertical Pharmaceuticals, LLC1$15
Mallinckrodt Hospital Products Inc.1$13

How this compares

$1,722,299 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$343,766
Medicare patients
685
Services billed
2,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Aventura

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →